ISM 9182A
Alternative Names: ISM-9182ALatest Information Update: 11 Jul 2024
At a glance
- Originator InSilico Medicine
- Class Antineoplastics
- Mechanism of Action Hematopoietic progenitor kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 12 Jun 2024 Adverse event, pharmacodynamics and pharmacokinetics data from preclinical trials in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 05 Apr 2024 Preclinical trials in Solid tumours in USA (unspecified route), prior to April 2024